Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WJ01024 Monotherapy and in Combination With Ruxolitinib in Patients With Myelofibrosis
NCT07802405Phase 1Recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Nov 2023
- Primary completion
- Sep 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of WJ01024 in myelofibrosis (MF), sponsored by Henan Cancer Hospital. Primary endpoints: Dose-Limiting Toxicity at 12 months, Adverse Events at 4 years and 2 more. Started Nov 2023; status: recruiting.
02
Drugs
WJ01024
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT07802405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07802405.